Lineage Cell Therapeutics, Inc. Share Price
AMEX: LCTX | Micro CapLineage Cell Therapeutics, Inc. Stock Performance
Open $1.13 | Prev. Close $1.14 | Circuit Range N/A |
Day Range $1.08 - $1.14 | Year Range $0.95 - $2.08 | Volume 59,370 |
Average Traded $1.11 |
Lineage Cell Therapeutics, Inc. Share Price Today
As of 10 August 2026, Lineage Cell Therapeutics, Inc.'s share price is $1.10. The stock opened at $1.13, compared to its previous close of $1.14. During today's trading session, Lineage Cell Therapeutics, Inc.'s share price traded between $1.08 and $1.14, with an average price of $1.11. Over the past 52 weeks, the stock has recorded a high of $2.08 and a low of $0.95. In terms of performance, Lineage Cell Therapeutics, Inc.'s share price has declined by 42.56% over the last six months and is down 6.38% on a year-on-year basis.
Lineage Cell Therapeutics, Inc. Share Price Chart
Lineage Cell Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $253.13M | PE Ratio (TTM) -3.93 | Dividend Yield N/A |
EPS (TTM) $-0.28 | Revenue (TTM) $14.56M | Return On Equity (TTM) -142.24% |
Profit Margin -435.33% | Debt to Equity 0.26 | Quarterly Earnings Growth YoY -881.58% |
Lineage Cell Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Lineage Cell Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.09 | $1.10 | +1.84% |
Jul 2026 | $1.32 | $1.08 | -17.49% |
Jun 2026 | $1.34 | $1.31 | -0.38% |
May 2026 | $1.50 | $1.32 | -13.16% |
Apr 2026 | $1.58 | $1.52 | -3.18% |
Mar 2026 | $1.88 | $1.57 | -18.02% |
Feb 2026 | $1.48 | $1.92 | +31.16% |
Jan 2026 | $1.66 | $1.46 | -12.31% |
Dec 2025 | $1.72 | $1.67 | -4.86% |
Nov 2025 | $1.97 | $1.75 | -9.09% |
Oct 2025 | $1.72 | $1.93 | +13.57% |
Sep 2025 | $1.20 | $1.70 | +44.26% |
LCTX Share Price FAQs
What is Lineage Cell Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Lineage Cell Therapeutics, Inc. stock?
What is LCTX's market capitalisation today?
What is LCTX's net income for the last quarter?
What is the 5 year returns of LCTX?
What is the high & low stock price of LCTX today?
Can I buy LCTX shares in India?